Converge Bio
Generative AI for drug development
CORE INFO
Converge Bio is at the forefront of revolutionizing drug development by leveraging generative AI technologies. Founded in 2024, the company has developed a unified AI platform that integrates seamlessly into existing drug development workflows. This platform offers solutions such as AI-driven antibody design and screening, gene expression optimization, and target and biomarker discovery. These innovations aim to streamline processes, enhance protein yields, and identify disease-driving targets, ultimately accelerating the drug discovery and development timeline. Operating out of Boston, Massachusetts, and Tel Aviv, Israel, Converge Bio has rapidly grown its team and client base. As of January 2026, the company employs 34 people and has completed over 40 programs with numerous pharmaceutical and biotech companies worldwide. Their mission is to empower these industries with AI solutions that enable faster and more effective drug discovery. The company's commitment to real-world impact is reflected in their values, which emphasize proof over promises and a solutions-first approach.
WHY WE WOULD WORK AT CONVERGE BIO
Innovative AI Solutions
Join a team that's pioneering generative AI in drug development, transforming how antibodies and biomarkers are discovered.
Rapid Career Growth
Be part of a fast-growing startup that has expanded from 9 to 34 employees in just two years, offering ample opportunities for advancement.
Real-World Impact
Contribute to over 40 successful programs with global pharmaceutical clients, accelerating drug discovery and improving patient outcomes.
Collaborative Culture
Work alongside a diverse team in Boston and Tel Aviv, united by a mission to empower biotech with AI-driven solutions.
Recognized Excellence
Join a company celebrated as a groundbreaking AI startup by industry leaders like Greenfield Partners and TechCrunch.
Competitive Compensation
Benefit from Series A funding of $25M, ensuring resources for competitive salaries and cutting-edge project development.
MARKET AND TRACTION
GROWTH TACTICS
KEY METRICS
✦ KEY METRICCOMPETITIVE ADVANTAGE
MARKET POSITION
SERVICES
PRODUCT AND TECH
AI-Driven Antibody Design
Utilizes generative AI for de novo antibody design, affinity maturation, and humanization, streamlining lead selection and reducing wet lab screening efforts.
Gene Expression Optimization
Employs AI to optimize codons, UTRs, promoters, and terminators, enhancing protein yields and mitigating bottlenecks in protein manufacturing.
Target & Biomarker Discovery
Simulates cellular responses across patient populations to identify disease-driving targets, facilitating the discovery of cell-type-specific targets linked to treatment responses.
Bio-LLM Library
Leverages a biological large language model library with foundation models across DNA, RNA, proteins, and small molecules, enhancing prediction, explainability, and generation capabilities.
Unified AI Platform
Integrates seamlessly into existing drug development workflows, providing comprehensive AI-driven solutions to accelerate drug discovery and development processes.